Actually, DNDN did run a couple of phase-2 trials in HRPC: 9901 and 9902a. True, these were called phase-3’s, but they resembled typical phase-2 trials for a large-indication cancer drug in size and rigor.
Thus, 9902b is the first real phase-3 Provenge trial and therein lies the problem: phase-2 results are less predictive of phase-3 results than many investors think due to a phenomenon I call program-survival bias.
For a striking example of program-survival bias in action, please see #msg-20614570.
Ok. Your assertion of "interim analysis stuff doomed to fail" implies knowledge and that got me curious. So I checked to see if you have something more concrete about the data, interim alpha, etc. Sounds like not.
News 
Market Data 
Discover 
AI
